Sign in
SBTX Stock Price, Chart, Stats & News
Silverback Therapeutics, Inc.
Save
Silverback Therapeutics, Inc. (SBTX) does not currently pay a dividend.
550.43M
Market cap
–
Current P/E
–
Forward P/E
SBTX chart
Price history is unavailable
We don't have enough price data for SBTX to draw a chart yet.
Fundamentals
Gross margin | 16.32% |
Operating margin | -212.92% |
Pretax margin | -203.35% |
Net margin | -203.25% |
Effective tax rate | 0.05% |
ROA | -52.28% |
ROE | -100.29% |
D/E | – |
Interest coverage ratio | 69.05x |
SBTX valuation
P/E | – |
P/S | 6.53x |
P/B | 5.06x |
P/CF | -3.39x |
P/FCF | -3.22x |
P/OCF | -3.39x |
PEG | 0.03x |
EV multiple | -3.30x |
About
Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immune response through the precise activation of TLR8 within the liver. The company was founded in 2016 and maintains its principal offices in Seattle, Washington.
Similar securities
Based on sector and market capitalization
Report issue